High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Rancea, Michaela ^a   Monsef, Ina ^a   von Tresckow, Bastian ^a   Engert, Andreas ^a   Skoetz, Nicole ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; MITOGUAZONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT;

ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; GASTROINTESTINAL DISEASE; HEART DISEASE; HIGH DOSE CHEMOTHERAPY; HODGKIN DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RESPIRATORY TRACT DISEASE; REVIEW; SEQUENTIAL HIGH DOSE CHEMOTHERAPY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RELATED MORTALITY; TREATMENT RESPONSE; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84891716143     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009411.pub2     Document Type: Review

References (73)

1. Linch DC, Winfield D, Goldstone AH, Moir D. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-4.
2. Schmitz N, Haverkamp H, Josting A, Carella AM. Long-term results of HD-R1: conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoetic stem cell transplantation in relapsed Hodgkin's disease [abstract]. European Journal of Haematology 2004;73 Suppl 65:57.
3. Schmitz N, Pfistner B, Sieber M, Carella AM. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71.
4. Schmitz N, Sextro M, Hasenclever D, Carella A. HD-R1: first results of a randomized trial comparing aggressive chemotherapy with high-dose therapy (HDT) and hematopoietic stem cell transplantation (HSCT) in patients with chemosensitive relapse of Hodgkin's disease (HD). Blood 1997;90(10):115a.
5. Schmitz N, Sextro M, Pfister B, Hasenclever D. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1) [abstract]. Journal of Clinical Oncology 1999;18:2a.
6. Engert A, Haverkamp H, Borchmann P, Mueller H. Final results of the hdr2 study - a European multicenter trial in patients with relapsed Hodgkin lymphoma [Abstract no. 0501]. Haematologica 2009;94 Suppl 2:204.
7. German Hodgkin Study Group. Phase III randomized study of induction chemotherapy followed by combination chemotherapy and autologous peripheral blood stem cell transplantation with or without high-dose sequential chemotherapy in patients with relapsed Hodgkin's lymphoma. clinicaltrials.gov/ct2/show/NCT00025636.
8. Glossmann JP, Josting A, Pfistner B, Paulus U. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Annals of Hematology 2009;81(8):424-9.
9. Josting A, Haverkamp H, Borchmann P, Dohner H. Fourth interim analysis of the HD-R2 study - a European multicenter trial for patients with relapsed Hodgkin lymphoma [abstract]. Haematologica 2007;92 Suppl 5:82-3.
10. Josting A, Mapara M, Reiser M, Draube A, et al.Interim analysis of a multicenter phase-II trial using high-dose sequential chemotherapy and autologous stem cell support for relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. Annals of Hematology 1998;77 Suppl 2:S214.
11. Josting A, Müller H, Borchmann P, Baars JW. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. Journal of Clinical Oncology 2010;28:5074-80.
12. Josting A, Rudolph C, Mapara M, Glossmann JP. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Annals of Oncology 2005;16(1):116-23.
13. Josting A, Rudolph C, Mapara M, Sieber M, et al.Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma - a large multicenter pilot study for the prospective randomized HDR-2 trial of the German Hodgkin Lymphoma Study Group (GHSG). Onkologie 2002;25 Suppl 4:195.
14. Josting A, Rudolph C, Mapara M, Sieber M, et al.Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma results of a large multicenter study for the prospective randomized HDR-2 trial of the German Hodgkin Lymphoma Study Group (GHSG). Blood 2002;100(11 Pt 2).
15. Avigdor A, Hardan I, Shpilberg O, Raanani P. High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy - studies at Sheba Medical Center -Tel Hashomer. Harefuah 2000;139(5-6):174-9.
16. Bolanos-Meade J, Garrett-Mayer E, Luznik L, Anders V. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biology of Blood & Marrow Transplantation 2007;13(10):1185-91.
17. Evens AM, Altman JK, Mittal BB, Hou N. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Annals of Oncology 2007;18(4):679-88.
18. Ferme C, Mounier N, Divine M, Brice P. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of Clinical Oncology 2002;20(2):467-75.
19. Gutierrez-Delgado F, Maloney DG, Holmberg LA, Hooper H. High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for patients with Hodgkin's disease (HD) - a comparison of two HDC regimens. Proceedings of the American Society of Clinical Oncology 2003;20:293a.
20. Kuruvilla J, Nagy T, Pintilie M, Saragosa A. Efficiency of stem cell mobilization after salvage chemotherapy with gemcitabine, dexamethasone, cisplatin (GDP) or mini-BEAM in patients with relapsed or refractory Hodgkin's lymphoma. 6th International Symposium on Hodgkin's Lymphoma. 2004.
21. Morschhauser F, Brice P, Ferme C, Divine M. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. Journal of Clinical Oncology 2008;26(36):5980-7.
22. Sweetenham JW, Taghipour G, Milligan D, Blystad AK. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 1997;20(9):745-52.
23. Van Agthoven M, Vellenga E, Fibbe WE, Kingma T. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. European Journal of Cancer 2001;37(14):1781-9.
24. Vellenga E, Van Agthoven M, Croockewit AJ, Verdonck LF. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. British Journal of Haematology 2001;114(2):319-26.
25. Waever CH, Schwartzberg LS, Upton S, Birch R. Interim analysis of a randomized phase III trial comparing high-dose busulfan, melphalan and thiotepa (BuMeIT) with carmustine, etoposide, cytosine arabinoside and cyclophosphamide (BEAC) followed by peripheral blood stem cell (PBSC) infusion in patients with relapsed Hodgkin's disease (HD). Blood 1996;88(10):289b.
26. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society Atlanta: 2010.
27. Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al.Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology 2003;14(12):1762-7. [PUBMED: 14630682]
28. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, Van Besien K. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology 2007;18(6):1071-9.
29. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, et al.Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005;105(11):4215-22.
30. Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, et al.High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. European Journal of Haematology 2001;64:51-5. [PUBMED: 11486403]
31. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research 1971;31(11):1860-1.
32. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. Journal of Clinical Oncology 2005;23(26):6400-8.
33. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. 2011. Available from www.cochrane-handbook.org.
34. Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, et al.Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavourable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of Clinical Oncology 2010;28(27):4199-206.
35. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al.Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favourable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology 2007;25(23):3495-502.
36. Engert A, Haverkamp H, Borchmann P, Mueller H, Diehl V, Döhner B, et al.Final results of the HD-R2 study - a European multicenter trial in patients with relapsed Hodgkin lymphoma. Haematologica 2009.
37. Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of Clinical Oncology 2002;20(2):467-75.
38. Franklin J, Eichenauer D, Monsef I, Engert A. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD008814]
39. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. Version 3.2 for Windows. Cochrane IMS, 2008.
40. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. 2011. Available from www.cochrane-handbook.org.
41. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. 2011. Available from www.cochrane-handbook.org.
42. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. 2011. Available from www.cochrane-handbook.org.
43. Horning SJ. Risk, cure and complications in advanced Hodgkin disease. Hematology 2007;2007:197-203.
44. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al.New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. Journal of Clinical Oncology 2002;20(1):221-30.
45. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al.Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Annals of Oncology 2002;13(10):1628-35. [PUBMED: 12377653]
46. Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. Journal of Clinical Oncology 2010;28(34):5074-80.
47. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208-17. [PUBMED: 21263152]
48. Kurvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology/The Education Program of the American Society of Hematology. Washington: American Society of Hematology (ASH), 2009:497-506.
49. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. 2011. Available from www.cochrane-handbook.org.
50. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al.Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-4.
51. Martin A, Fernandez-Jimenez MC, Caballero MD, Canales MA, Perez-Simon JA, Garcia de Bustos J, et al.Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. British Journal of Haematology 2001;113(1):161-71. [PUBMED: 11328296]
52. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
53. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al.A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97(3):616-23.
54. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology Hodgkin disease/lymphoma. www.nccn.org/professionals/physician_gls/f_guidelines.asp 2012.
55. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
56. Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, et al.Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Annals of Oncology 2003;14 Suppl 1:i47-50. [PUBMED: 12736232]
57. Rancea M, Engert A, Von Tresckow B, Halbsguth T, Behringer K, Skoetz N. Clinical practice guideline: Hodgkin's lymphoma in adults - diagnosis, treatment and follow-up. Deutsches Ärzteblatt International 2013;110(11):177-83.
58. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
59. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al.Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92(1):35-41.
60. Sasse S, Alram M, Mueller H, Smardova L, Metzner B, Döhner H, Fischer T, et al.Prognostic relevance of dose-density of DHAP-reinduction therapy in relapsed HL: an analysis of the German Hodgkin-Study Group (GHSG). Proceeding of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta (GA). 2012.
61. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al.Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359(9323):2065-71.
62. Schuenemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings tables'. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. 2011. Available from www.cochrane-handbook.org.
63. Smith SD, Moskowitz CH, Dean R, Pohlman B, Sobecks R, Copelan E, et al.Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. British Journal of Haematology 2011;153(3):358-63. [PUBMED: 21410449]
64. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. 2011. Available from www.cochrane-handbook.org.
65. Sureda A, Younes A, Ben-Yehuda D, Ong T-C, Kaufman JL, Le Corre C, et al.Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. Proceedings of the 52nd Annual Meeting and Exposition; 2010 Dec 4-7; Orlando (FL). 2010.
66. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al.Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97(2):310-7.
67. Swerdlow AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging 2003;30 Suppl 1:S3-12.
68. Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Annals of Oncology 2002;13 Suppl 4:147-52.
69. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
70. Von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Current Hematologic Malignancy Reports 2011;6:1-8.
71. Weaver CH, Zhen B, Buckner CD. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells. Bone Marrow Transplantation 1998; Vol. 21, issue 11:1169-70. [PUBMED: 9645585]
72. Weiss LM. Epstein-Barr virus and Hodgkin's disease. Current Oncology Reports 2000;2(2):199-204. [PUBMED: 11122844]
73. Younes A, Bartkett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al.Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New England Journal of Medicine 2010;363:1812-21.